Revenue
2015
2016
2017
2018
2019
2020
2021
2022
Decoy Therapeutics Inc. (DCOY)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.8M | $5.2M | $3.5M | $2.0M | $1.3M | $1.0M | $0 | $0 |
| Research & development | $8.5M | $0 | $7.2M | $15.8M | $8.5M | $6.9M | $4.0M | $1.3M | $17.0M | $20.4M | $12.7M | $4.0M |
| Operating expenses | $12.6M | $5.7M | $12.9M | $31.8M | $14.7M | $13.0M | $11.7M | $3.6M | $36.0M | $40.9M | $29.2M | $8.0M |
| Operating income | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M | −$8.3M | −$1.7M | −$34.7M | −$39.9M | −$29.2M | −$8.0M |
| EBITDAderived | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M | −$8.1M | −$1.7M | — | — | — | — |
| Net income | −$12.5M | −$5.6M | −$12.5M | −$31.6M | −$12.8M | −$7.4M | −$6.9M | −$1.7M | −$34.4M | −$39.5M | −$29.1M | −$8.0M |
| Basic EPSper diluted share | -$129.10 | -$69.54 | -$30.74 | -$14.88 | -$7.72 | -$0.50 | -$2.12 | -$1.16 | -$1.99 | -$2.43 | -$2.08 | -$4.57 |
| Diluted EPSper diluted share | -$129.10 | -$69.54 | -$30.74 | -$14.88 | -$7.72 | -$0.50 | -$2.12 | -$1.16 | -$1.99 | -$2.43 | -$2.08 | -$4.57 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 30, 2025Form 4 | HANISH ARNOLD CDirector | SellCommon Stock | 12 | $0.64 | $7.68 | 0 |
| Dec 30, 2025Form 4 | HANISH ARNOLD CDirector | SellCommon Stock · indirect | 15 | $0.64 | $9.60 | 5.0K |
| Nov 20, 2025Form 4 | HANISH ARNOLD CDirector | BuyCommon Stock · indirect | 5.0K | $0.75 | $3.8K | 5.0K |
| Nov 20, 2025Form 4 | Rosenblum Mark JExec VP Finance, CFO | BuyCommon Stock | 20.0K | $0.80 | $16.0K | 20.2K |